LPIN1 and non-small cell lung carcinoma: Additionally, we found that LPIN1 knockdown clearly decreased both the basal and gefitinib treatment-induced DAG contents and increased PA contents in gefitinib-resistant H1650 NSCLC cells (Figure 2B and Figure S5).